IL-7 Binding Proteins and Their Use in Medical Therapy
Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
1 - 35 . (canceled)
36 . A method for the treatment of an autoimmune and/or inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an interleukin 7 (IL-7) binding protein or IL-7 binding fragment thereof comprising:
(1) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 6;
(2) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 7;
(3) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 8;
(4) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 9;
(5) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 10; and
(6) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 11.
37 . The method of claim 36 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 4 and a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 5.
38 . The method of claim 37 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.
39 . The method of claim 36 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain having a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 2 and a light chain having a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 3.
40 . The method of claim 39 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3.
41 . The method of claim 36 , wherein the IL-7 binding protein or IL-7 binding fragment thereof is an antibody.
42 . The method of claim 41 , wherein the antibody comprises an IgG1 or IgG4 Fc region.
43 . The method of claim 42 , wherein the antibody comprises a human IgG1 heavy chain constant region.
44 . The method of claim 43 , wherein the antibody comprises a human IgG1 heavy chain constant region having an alanine residue at position 235 and position 237 according to EU numbering.
45 . The method of claim 36 , wherein the autoimmune and/or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, or type I diabetes.
46 . The method of claim 45 , wherein the multiple sclerosis is clinically isolated syndrome, relapsed remitting, primary progressive or secondary progressive.
47 . The method of claim 45 , wherein the autoimmune and/or inflammatory condition is systemic lupus erythematosus.
48 . The method of claim 45 , wherein the autoimmune and/or inflammatory condition is inflammatory bowel disease.
49 . The method of claim 45 , wherein the autoimmune and/or inflammatory condition is type 1 diabetes.
50 . The method of claim 38 , wherein the autoimmune and/or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, or type I diabetes.
51 . The method of claim 50 , wherein the multiple sclerosis is clinically isolated syndrome, relapsed remitting, primary progressive or secondary progressive.
52 . The method of claim 50 , wherein the autoimmune and/or inflammatory condition is systemic lupus erythematosus, inflammatory bowel disease, or type I diabetes.
53 . The method of claim 50 , wherein the autoimmune and/or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, or type I diabetes.
54 . The method of claim 53 , wherein the multiple sclerosis is clinically isolated syndrome, relapsed remitting, primary progressive or secondary progressive.
55 . The method of claim 53 , wherein the autoimmune and/or inflammatory condition is systemic lupus erythematosus, inflammatory bowel disease, or type I diabetes.